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Abstract
Background: Compound A (CpdA) is a dissociating non-steroidal glucocorticoid receptor (GR) ligand which has anti-
inflammatory properties exerted by down-modulating proinflammatory gene expression. By favouring GR monomer
formation, CpdA does not enhance glucocorticoid (GC) response element-driven gene expression, resulting in a reduced
side effect profile as compared to GCs. Considering the importance of Th1/Th2 balance in the final outcome of immune and
inflammatory responses, we analyzed how selective GR modulation differentially regulates the activity of T-bet and GATA-3,
master drivers of Th1 and Th2 differentiation, respectively.
Results: Using Western analysis and reporter gene assays, we show in murine T cells that, similar to GCs, CpdA inhibits T-bet
activity via a transrepressive mechanism. Different from GCs, CpdA induces GATA-3 activity by p38 MAPK-induction of
GATA-3 phosphorylation and nuclear translocation. CpdA effects are reversed by the GR antagonist RU38486, proving the
involvement of GR in these actions. ELISA assays demonstrate that modulation of T-bet and GATA-3 impacts on cytokine
production shown by a decrease in IFN-c and an increase in IL-5 production, respectively.
Conclusions: Taken together, through their effect favoring Th2 over Th1 responses, particular dissociated GR ligands, for
which CpdA represents a paradigm, hold potential for the application in Th1-mediated immune disorders.
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Introduction
Glucocorticoids (GCs) are the most potent and frequently used
anti-inflammatory drugs for a variety of Th1- and Th2-mediated
immune disorders. Nevertheless, long-term applications are often
complicated by severe adverse effects [1]. GCs act via binding to
the glucocorticoid receptor (GR), a transcription factor (TF)
belonging to the nuclear receptor superfamily. It is widely
accepted that the desired anti-inflammatory effects of GCs are
caused by the interaction of the monomeric GR with the activity
of other TFs that drive proinflammatory gene expression, whereas
the direct binding of GR to GC response elements (GREs)
resulting in the direct transcription of target genes is mostly
associated with well-known endocrine side effects [2]. This has led
to the search for selective GR modulators, such as dissociated GR
ligands, that selectively transrepress and which are predicted to
reduce the appearance of a wide range of side effects. As the quest
for dissociated steroidal GR ligands did not quite live up to
expectations, there is currently a renewed interest of the
pharmaceutical industry to find non-steroidal selective GR
modulators with a reduced side effect profile yet maintaining
their therapeutic efficacy [3].
Compound A (CpdA) is a stable analog of the hydroxy phenyl
aziridine precursor found in the Namibian shrub Salsola tubercu-
latiformis Botschantzev [4]. CpdA is a clearly dissociating
compound [4]. This means that it does not stimulate GRE-driven
gene expression. It has been shown that CpdA and the synthetic
GC dexamethasone (Dex) interact with the GR with comparable
affinities, in the nanomolar range, but varying dependent on the
cell type [4,5]. The specific gene-repressive effect of CpdA
depends on the presence of functional monomeric GR [6],
displaying a differential phosphorylation status as compared to
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Dex [4]. The anti-inflammatory mechanism of CpdA involves
both a reduction of DNA-binding activity, as well as an
interference with the transactivation potential of NF-kB [4],
which plays a central role in inflammation. Analysis of diverse
mouse models of inflammatory and autoimmune diseases further
supports the idea that CpdA has a potent anti-inflammatory
activity and particularly lacks diabetogenic and bone metabolism
side effects when applied in vivo compared with GCs [4,6–10].
The adaptive immune response is triggered when T cells
recognize antigens, which have been presented by antigen
presenting cells. GATA-3 [11] is a master TF involved in Th2
development [12]. Th2 cytokines promote B cell-mediated
humoral immunity against extracellular pathogens [13]. Th2
cytokines include IL-4, IL-5, IL-13 and IL-10. Ectopic expression
of GATA-3 in developing and fully committed Th1 cells gives rise
to Th2 cytokine production as well as Th1 cytokine inhibition
[14]. GATA-3 regulates Th2 cytokine expression not only at the
transcription level, by directly binding to the IL-5-promoter, but
also by remodeling the chromatin structure and opening the IL-4
locus [15]. As a master control, GATA-3 stabilizes the Th2
phenotype in three ways [16]. First, GATA-3 shuts down Th1
development by down-regulation of STAT4/IL-12Rbeta2 chain
or T-bet. Second, GATA-3 augments its own expression by a
positive feedback autoregulation [17]. Third, GATA-3 favors
selective growth of Th2 cells [16]. In Th2 cells [18], cAMP induces
GATA-3 phosphorylation via p38 MAPK and stimulates GATA-
3-dependent promoter activities [18,19]. Intracellular increments
of cAMP levels in Th cells are associated with an augmentation of
Th2 cytokine production via GATA-3 and protein kinase A (PKA)
activation [20].
T box expressed in T cells (T-bet) is a Th1 specific TF that
controls the expression of the potent proinflammatory cytokine
IFN-gamma (IFN-c) [21], hallmark of Th1 cell-mediated immu-
nity [22,23]. Over-expression of T-bet into primary T cells or even
fully polarized Th2 cells is able to generate IFN-c-producing Th1
cells, concomitant with an inhibition of the production of the Th2
cytokines IL-4 and IL-5 [21]. T-bet deficient mice show normal
lymphoid development, but profound defects in mounting a Th1
immune response and a corresponding increase in Th2 cytokines
[24]. T-bet may down-regulate GATA-3 function either by
regulating its expression or by inhibiting its activity [21,25].
We have previously described that GCs inhibit the transcrip-
tional activity of T-bet [26] by a transrepression mechanism
involving a protein-protein interaction between the activated GR
and T-bet, resulting in a diminished DNA binding [26]. Also the
master Th2 TF GATA-3 is inhibited by GCs, yet via a different
molecular mechanism. GCs inhibit GATA-3 activity by the
inhibition of p38 MAPK-induced GATA-3 phosphorylation and
its nuclear translocation [27,28]. Therefore, by suppressing Th1
responses to a stronger extent than Th2, GCs favor a shift from a
Th1 towards a Th2 profile, which might have relevant
implications in the treatment of Th1-polarized immune disorders
[26,29].
In order to discover novel targets in relevant immune-
modulatory pathways that may be differentially affected by
nonconventional GR modulators such as CpdA, and hence may
become of direct clinical relevance, a detailed understanding of the
molecular mechanism underlying the immune-modulatory effects
of GCs and dissociated GCs in immune cells is a prerequisite.
Although recent data regarding the effect of CpdA on the
expression of Th cytokines in various animal models of immune
diseases has been presented [7,8], the molecular mechanism
underlying differential effects of a selective modulation of GR in
immune cells on downstream TF targets has not yet been clarified.
To this purpose, we investigated how CpdA- and Dexamethasone
(Dex)-activated GR differentially affect the activity of key TFs
involved in the regulation and final outcome of Th-mediated
immune responses.
Results
CpdA Inhibits the Transcriptional Activity of T-bet
We established before that conventional GR activation, through
the use of the classic GC Dexamethasone (Dex), can negatively
impact on the activity of T-bet [26]. At present it is unknown
whether or not selective GR modulation, through the use of the
dissociated GR modulator CpdA, can regulate the activity of
immune-regulatory TFs, other than NF-kB. Hence, we investi-
gated whether CpdA could also negatively regulate the transcrip-
tional activity of the key Th1 TF T-bet. Transfection of EL4 T
cells with T-bet response elements cloned upstream of the
luciferase gene (T-bet-RE-Luc) together with GR (CMV-hGR)
and T-bet (pcDNA3-T-bet) expression vectors in the presence of
increasing amounts of CpdA led to a dose-dependent inhibition of
T-bet’s transcriptional activity (Fig. 1A), similar to the effect we
have previously reported for GCs (Fig. 1A, striped bar) [26]. The
antagonistic effect exerted by RU38486 proved that the ligand-
binding domain of GR is involved in CpdA-mediated inhibition of
T-bet activity (Fig. 1A). In addition, no effect of CpdA was
observed when the GR was absent from the transfection
experiments. Similar results were obtained using the human
Jurkat T cell line (data not shown).
Western Blot assays performed under similar conditions as
mentioned above, showed that CpdA does not affect the over-
expressed protein levels of T-bet (Fig. 1B), strongly suggesting that
CpdA directly targets T-bet at the transcriptional level.
CpdA Inhibits the Transcriptional Activity of T-bet via a
Transrepression Mechanism
Taking into account that GCs inhibit T-bet activity via
transrepression and that CpdA does not transactivate GRE-
dependent genes but can transrepress cytokine genes [4], we
analyzed whether the underpinning mechanism by which CpdA
inhibits T-bet activity could be transrepression. To adress this
hypothesis we used two extensively described GR mutants
[26,30,31]. A458T is a D-loop dimerization interface mutation
that blocks GR dimerization and activation of transcription [31].
S425G is a DBD mutant that has a serine to glycine substitution at
position 425, which removes a hydroxyl group supposed to alter
bondings between the zinc finger domain and other proteins and
hence disrupts transrepression [30]. Transfection and recombinant
reporter gene analyses in EL4 cells show that CpdA-activated
wild-type GR, but not CpdA-activated S425G GR, the GR
mutant defective for transrepression, was able to transrepress kB-
Luc activity (Fig. 2A). On the contrary, CpdA retained its
transrepressive capacity when triggering the A458T GR-transac-
tivation defective mutant (Fig. 2A). Neither the wild-type nor the
mutant GRs could transactivate TK-GRE2-Luc in the presence of
CpdA (Fig. 2B), confirming its dissociated activity also in immune
cells. As expected, Dex, the classic GC, behaved similar as CpdA
in the transrepression assays (Fig. 2A, striped bars), and opposite to
CpdA in the transactivation assays (Fig. 2B, striped bars).
Concerning the effect of a dissociative GR modulation on the
T-bet-RE-Luc reporter gene activity, we found that both CpdA-
activated wild-type GR and A458T, the GR-transactivation
mutant, can strongly inhibit T-bet activity. On the contrary,
CpdA-activated S425G GR mutant displayed a reduced ability in
repressing T-bet activity, when compared to the strong inhibition
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exerted by the CpdA-treated wild-type and A458T mutant. These
data, using mutant GR and/or the dissociative activity of a GR
ligand, are in line with a mechanism whereby the transrepressive
function of GR can be exclusively held responsible for the GR-
mediated inhibition of T-bet activity.
CpdA Inhibits T-bet-driven IFN-c Gene Expression and
Protein Production
We tested the functional relevance of CpdA-mediated inhibition
of T-bet transcriptional activity on IFN-c, hallmark of Th1-
mediated immune responses [21]. To investigate whether CpdA-
dependent inhibition of T-bet activity can be observed in a
functionally relevant promoter context, i.e. on the IFN-c
promoter, EL4 cells were transfected with a -3447-IFN-c
promoter cloned upstream of the luciferase gene together with
the GR expression vector. Over-expression of T-bet resulted in a
strong increase of the luciferase activity, whilst cotransfection of
GR in the presence of CpdA led to the inhibition of IFN-c-
promoter activity (Fig. 3A). No effect of CpdA was observed when
GR was absent from the transfection experiments. Under the same
conditions as in the transfection experiments, Western Blots were
carried out to analyze T-bet protein expresion. No changes in the
over-expressed T-bet protein levels were observed following CpdA
treatment (data not shown), suggesting that the CpdA-mediated
inhibition of T-bet is at the transcriptional level and a relevant
mechanism in the regulation of the IFN-c promoter. Next, we
analyzed whether the transcriptional repression of CpdA could
also be reflected in a diminished IFN-c protein production in
purified CD4+ T cell cultures. Indeed, Fig. 3B shows that CpdA
strongly inhibits IFN-c production. Similar results were obtained
in non-adherent and in total splenocyte cultures (data not shown).
CpdA Induces the Transcriptional Activity of GATA-3 by
Signaling Through p38 MAPK
To determine whether CpdA also regulates the transcriptional
activity of the master Th2 TF GATA-3, we transfected EL4 cells
with a GATA-3-dependent reporter gene construct (GATA-3-RE-
Luc) together with GR (CMV-hGR) and GATA-3 (pcDNA3-
GATA-3) expression vectors (Fig. 4A). Contrary to the effect we
have previously described for GCs [27], increasing amounts of
CpdA, in the presence of cAMP, led to a dose-dependent
induction of GATA-3 activity (Fig. 4A).
The reversion by the specific antagonist RU38486 proved that
the ligand-binding module of the GR is involved in the CpdA-
mediated induction of GATA-3 activity (Fig. 4A). In addition, no
effect of CpdA was observed when GR was not present in the
transfection experiment. Similar results were obtained using Jurkat
cells (data not shown).
As the induction of GATA-3 activity could be the consequence
of an increased GATA-3 protein expression, we analyzed over-
expressed GATA-3 protein levels by Western Blot under the same
conditions as in the transfection experiments. We observed no
changes in GATA-3 protein levels, strongly suggesting that CpdA
induces GATA-3 transcriptional activity (Fig. 4B).
As previously described, cAMP treatment enhances the activity
of GATA-3 via p38 MAPK induction [18–20,27]. Therefore, in
order to study the effect of CpdA on the activity of this kinase, EL4
cells were transfected with a GATA-3-dependent reporter gene
construct (GATA-3-RE-Luc) together with GR (CMV-hGR) and
GATA-3 (pcDNA3-GATA-3) expression vectors. CpdA-induced
GATA-3 activity was inhibited in the presence of the kinase
inhibitor SB203580 (Fig. 4C), supporting the involvement of the
p38 MAPK pathway for CpdA-induced GATA-3 activity.
Overexpressing p38 MAPK, using a p38 expression vector
Figure 1. Compound A inhibits T-bet transcriptional activity. A, EL4 cells were transfected with 9 mg of a reporter plasmid which contains T-
bet response elements upstream of the luciferase gene (T-bet-RE-Luc) with or without 9 mg of T-bet and GR expression vectors. After 16 h in culture,
cells were stimulated for 5 h with or without Compound A (CpdA, 0.1, 1, 5 and 10 mM), Dexamethasone (Dex, 10 nM) or the GR specific antagonist
RU38486 (1 mM). Results, as folds, normalized to b-galactosidase activity, are expressed as mean 6 SEM (n = 6, * p,0.001 vs. basal without T-bet,
** p,0.05 vs. T-bet without CpdA), averaged from three independent experiments. B, Lysates obtained from transfection experiments performed
under similar conditions as mentioned above, were prepared for T-bet analysis by Western Blot. Single bands corresponding to T-bet were obtained.
GAPDH signal was used as loading control; one of three independent experiments with similar results is shown.
doi:10.1371/journal.pone.0035155.g001
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(pcEFL-p38a), resulted in a further increase of CpdA- and cAMP-
induced GATA-3 activities. These results confirm an important
role for p38 MAPK in driving the activity of GATA-3, elicited by
two different (Fig. 4D).
To test whether the molecular mechanism by which CpdA
induces the transactivation of GATA-3 involves CpdA-mediated
p38 phosphorylation, we performed Western Blot assays in EL4
cells transfected with a GR expression vector (CMV-hGR) in the
presence of CpdA and cAMP (Fig. 4E). The results demonstrate
that CpdA already on its own strongly induces p38 phosphory-
lation, and that the effect is enhanced in the presence of cAMP.
Phosphorylation and activation of the downstream TF ATF2 is
known to reflect an activation of the p38 MAPK signaling
pathway [32]. A chimeric trans-activator protein containing ATF2
fused to the DNA binding domain of the yeast transcriptional
activator GAL4 (pFA-ATF2) was transiently transfected into cells
with a luciferase reporter containing five copies of a GAL4 DNA
binding element upstream of a TATA box and the luciferase gene
(pG5-Luc). Thus, by monitoring the activity of the pG5-Luc
reporter, the activation of ATF2 by p38 MAPK was followed.
Fig. 4F shows that CpdA strongly induces the reporter activity and
SB203580 inhibits this induction further confirming that CpdA is
able to induce p38 MAPK activity.
PKA, MEK-1 and JNK pathways are not involved as shown by
the lack of inhibition of CpdA-induced GATA-3 activity using the
specific inhibitors of these kinases H89, PD98059 and SP600125
respectively (data not shown).
CpdA Induces Phosphorylation and Nuclear
Translocation of GATA-3
It has been reported that p38 MAPK induces GATA-3
phosphorylation and nuclear translocation, which impacts on the
transcriptional activity of GATA-3 [19]. To directly investigate
whether the effect of CpdA on p38-mediated GATA-3 activity
involves the induction of GATA-3 phosphorylation [27,28],
Western Blots were performed using EL4 cells stimulated under
basal, cAMP- and CpdA-activating conditions using a specific
antibody against phospho-GATA-3 (p-GATA-3). As shown in
Fig. 5A, although CpdA does induce a slight GATA-3 phosphor-
ylation on its own; in the presence of cAMP, this effect is
significantly enhanced. As expected, also cAMP on its own induces
phosphorylation of GATA-3. Whole extract lysates were used as
controls for total GATA-3 expression (Fig. 5A).
To address whether CpdA further enhances the nuclear
translocation of GATA-3, we performed Western Blot experi-
ments using cytoplasmic and nuclear extracts. Fig. 5B shows that
as previously reported, cAMP induces GATA-3 nuclear translo-
cation. An additional treatment with CpdA further induces this
translocation. A specific antibody against Histone H3 was used as
control to demonstrate the purity of the nuclear extracts and
GAPDH was used as control of the cytoplasmic extracts (Fig. 5B).
Figure 2. Compound A inhibits T-bet transcriptional activity by transrepression. A, EL4 cells were cotransfected with 9 mg of kB-Luc
reporter plasmid and 9 mg of Rel A plus 9 mg of phGR-SB (wt) wild-type GR expression vectors or the GR mutants A458T or S425G. After 16 h, cells
were stimulated for 8 h with IL-1b (10 ng/ml), which induces kB-Luc activity, and with CpdA (10 mM) or Dex (100 nM). Results, as % of inhibition of
kB-Luc, normalized to b-galactosidase activity, are expressed as mean 6 SEM (n = 3, * p,0.001 vs. Rel A plus IL-1b without Dex or CpdA), of one
representative experiment of three independent experiments with similar results. B, EL4 cells were transfected with 9 mg of a reporter plasmid
containing two palindromic GR-binding sites coupled to the TK promoter reporter plasmid (TK-GRE2-Luc) plus 9 mg of phGR-SB (wt) wild-type GR
expression vector or the GR mutants A458T or S425G. After 16 h, cells were stimulated for 5 h with CpdA or Dex. Results, as % of activation of TK-
GRE2-Luc, normalized to b-galactosidase activity, are expressed as mean 6 SEM (n = 3, * p,0.05 vs. basal without Dex or CpdA, ** p,0.05 vs. Dex
treated wild-type or S425G mutant GR), of one representative experiment of three independent experiments with similar results. C, EL4 cells were
transfected with 9 mg of T-bet-RE-Luc reporter plasmid and with 9 mg of T-bet and wild-type GR expression vectors (ph-GR-SB) or the GR mutants
A458T or S425G. After 16 h, cells were stimulated for 5 h with CpdA. Results, as % of inhibition of T-bet-RE-Luc, normalized to b-galactosidase activity,
are expressed as mean 6 SEM (n = 3, * p,0.001 vs. ph-GR-SB or A458T-mediated T-bet-RE-Luc relative inhibition) of one representative experiment
of three independent experiments with similar results.
doi:10.1371/journal.pone.0035155.g002
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CpdA Induces GATA-3-driven IL-5 Gene Expression and
Protein Production
To investigate the possible involvement of CpdA-dependent
induction of GATA-3 activity in the regulation of IL-5, a central
Th2 cytokine, EL4 cells were transfected with the IL-5 promoter
cloned upstream of the luciferase gene together with GR (CMV-
hGR) and GATA-3 (pcDNA3-GATA-3) expression vectors. Over-
expression of GATA-3 in the presence of CpdA led to strong
induction of IL-5 activity (Fig. 6A). The involvement of p38
MAPK was evident because CpdA-induced GATA-3 activity was
inhibited in the presence of the specific kinase inhibitor SB203580.
To confirm the involvement of GATA-3 on CpdA-mediated IL-
5 promoter activity, we transfected EL4 cells with the proximal IL-
5 promoter (2120 to +44) bearing its unique GATA-3 binding site
(around position 272), or its mutated version on the GATA-3
binding site (IL5-Gm-luc) (Fig. 6B). CpdA induces the wild-type
IL-5 promoter activity but its effect is strongly inhibited upon using
the promoter variant containing the mutated GATA-3 binding
site, confirming the importance of GATA-3 in mediating the
CpdA-activated promoter activity.
The A20 mouse B lymphoma cell line, which does not express
endogenous GATA-3 but expresses endogenous GR, was
transfected with the IL-5 promoter-driven reporter gene construct
in the presence or absence of a GATA-3 expression vector. There
was no IL-5 promoter activity in the absence of GATA-3 and
when GATA-3 is overexpressed, CpdA is able to further induce
the activity of cAMP-stimulated GATA-3, confirming that the IL-
5 promoter is induced by a CpdA-modulated GATA-3 activity
(Fig. 6C).
Next, we analyzed whether the transcriptional activation of
CpdA could also be reflected in an increase of IL-5 protein
production in purified CD4+ T cell cultures. Indeed, Fig. 6D
shows that CpdA strongly induces IL-5 production. Similar results
were obtained in non-adherent and in total splenocyte cultures
(data not shown).
Discussion
In this work we describe the mechanisms of action following
selective GR modulation in immune T cells. Hereto, we studied
the effect of CpdA, as a paradigm for a dissociative GR activity, on
the activity of key Th TFs that control the development and final
outcome of the adaptive immune responses: T-bet, involved in
Th1 cellular immunity; and GATA-3, involved in Th2 humoral
immune responses.
Our findings demonstrate that in T cell lines, CpdA inhibits the
transcriptional activity of T-bet via a mechanism involving GR-
mediated transrepression, similar to the effect previously described
for GCs [26]. On the other hand, different from the mechanism
that was previously described for GCs on GATA-3 activity [27],
CpdA induces the transcriptional activity of GATA-3 via an
enhanced induction of p38 MAPK-mediated GATA-3 phosphor-
ylation and subsequent nuclear translocation. Considering that in
rats with experimental autoimmune neuritis, CpdA treatment
increased the numbers of anti-inflammatory M2 macrophages and
inhibited the mRNA expression of inflammatory cytokines [8],
CpdA may have a dual effect on immune cells: 1) on macrophages
to dampen an uncontrolled first line of defense, and 2) modulation
of the Th1-Th2 balance in the second stage.
Since nothing is known yet about the regulation of key Th
immune-regulatory TFs, we first investigated the role of CpdA on
the transcriptional activity of T-bet in T cells. We transfected EL4
cells with a construct bearing T-bet response elements cloned
upstream of the luciferase gene and found that CpdA strongly
inhibits the transcriptional activity of T-bet. The actions of CpdA
were reverted by the synthetic antagonist RU38486 which acts as
a competitor for ligand binding to GR, unambiguously demon-
strating direct GR involvement.
It is generally accepted that DNA binding and subsequent
activation of gene expression requires the dimerization of GR and
Figure 3. Compound A inhibits IFN-c promoter activity and
cytokine production. A, EL4 cells were cotransfected with 9 mg of
IFN-c promoter-driven luciferase plasmid (IFN-c-Luc) plus 9 mg of GR
expression vector and with 9 mg of T-bet expression vector. After 16 h
in culture, cells were stimulated for 5 h with Compound A (CpdA,
10 mM). Results, as folds, normalized to b-galactosidase activity, are
expressed as mean 6 SEM (n = 6, * p,0.001 vs. basal without T-bet,
** p,0.001 vs. T-bet without CpdA), averaged from three independent
experiments. B, Purification of T cells was achieved by a conventional
technique involving cell adhesion to plastic and then to a nylon wool
column and alternatevely by FACS sorting. Purified T cells were
activated with PMA (P) and Ionomycin (I) during 24 h and then
incubated with CpdA for 5 h. Supernatants were used to measure
mouse IFN-c according to the manufacturer’s instructions by ELISA.
Results are expressed as mean 6 SEM (n = 4, * p,0.001 vs. basal
without CpdA, ** p,0.001 vs. P+I without CpdA) of one representative
experiment of three independent experiments with similar results.
doi:10.1371/journal.pone.0035155.g003
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binding to a palindromic GRE [33]. Mutagenesis studies of the
GR DBD showed that disruption of the D-loop abolishes the
ability of GR to dimerize, thus inhibiting GC-mediated activation
[34]. On the other hand, a GR mutant harboring a point mutation
in the second zinc finger of the DBD was unable to repress
stimulated NF-kB but still could activate target genes through
GREs suggesting that activation and transrepression are separate
phenomena. As mentioned before, S425G DBD mutant has a
serine to glycine substitution at position 425, which removes a
hydroxyl group supposed to alter bondings between the zinc finger
domain and other proteins such as T-bet [26]. Our finding that
the first zinc finger of the DBD is important for CpdA and GC-
mediated inhibition of T-bet activity strongly suggests that this
region is essential for transrepression between the GR and T-bet.
IFN-c is a strong activator of inflammatory responses and
cellular immunity. Studies of the IFN-c gene promoter have
shown that T-bet elements play an important role in the induction
of transcription and production of this cytokine [21,24,35,36]. It
has been previously reported that CpdA inhibits IFN-c mRNA
expression and cytokine production in spinal cord and total
Figure 4. Compound A induces GATA-3 transcriptional activity by signaling through p38 MAPK. A, EL4 cells were transfected with 9 mg
of a reporter plasmid, which contains GATA-3 response elements upstream of the luciferase gene (GATA-RE-Luc) and with 9 mg of GATA-3 and GR
expression vectors. After 16 h, cells were stimulated for 5 h with Compound A (CpdA, 1, 5 and 10 mM), Dexamethasone (Dex, 10 nM), cAMP (0.3 mM)
and with the GR specific antagonist RU38486 (1 mM). n = 6, * p,0.001 vs. GATA-3 without CpdA and cAMP, ** p,0.001 vs. GATA-3 with cAMP and
without CpdA. B, Lysates obtained from transfection experiments performed under similar conditions as mentioned above, were analysed by Western
Blot. GAPDH was used as loading control. C, EL4 cells were transfected with 9 mg of GATA-RE-Luc reporter and with 9 mg of GATA-3 and GR
expression vectors. After 16 h, cells were stimulated for 5 h with CpdA (10 mM) and cAMP. Also, EL4 cells were pretreated during 1 h with the p38
MAPK inhibitor, SB203580 (10 mM). n = 6, * p,0.001 vs. GATA-3 without cAMP and CpdA, ** p,0.001 vs. GATA-3 with cAMP and without CpdA,
*** p,0.001 vs. GATA-3 with cAMP and CpdA. D, EL4 cells were transfected with 9 mg of GATA-RE-Luc reporter and 9 mg of GATA-3, GR and p38
MAPK expression vectors. After 16 h, cells were stimulated for 5 h with CpdA and cAMP. n = 6, * p,0.001 vs. GATA-3 without cAMP and CpdA, **
p,0.001 vs. GATA-3 with cAMP and without CpdA, *** p,0.001 vs. GATA-3 with cAMP and p38. E, EL4 cells were transfected with 20 mg of the GR
expression vector. After 16 h, EL4 cells were pretreated during 30 minutes with CpdA and then with cAMP during 25 minutes. Cell lysates were
prepared for Western Blot analysis against phospho-p38 (p-p38) MAPK. GAPDH and total p38 signals were used as loading controls. Lower panel: NIH
Image semiquantification. F, EL4 cells were transfected with 9 mg of pFA-ATF2 and 9 mg of pG5-Luc reporter plasmid, and the GR expression vector.
After 16 h, cells were stimulated for 5 h with CpdA and cAMP. Also, EL4 cells were pretreated during 1 h with the p38 MAPK inhibitor, SB203580. n =
6, * p,0.001 vs. basal without cAMP and CpdA, ** p,0.001 vs. cAMP without CpdA, *** p,0.001 vs. cAMP and CpdA. For all the transfections
experiments, results, as folds, normalized to b-galactosidase activity, are expressed as mean 6 SEM, averaged from three independent experiments.
doi:10.1371/journal.pone.0035155.g004
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splenocytes from mice with EAE [9] and also the mRNA
expression in lymph nodes of rats with EAN [8]. Our data add
onto these observations by demonstrating the inhibitory effect of
CpdA on PMA and Ionomycin-stimulated IFN-c production in
purified CD4+ T cells. Moreover, we continue to show that the
underlying molecular mechanism of IFN-c gene inhibition
following selective GR modulation involves the inhibition of T-
bet activity. Considering the previously reported inhibition of NF-
kB by CpdA [4], we speculate that other TFs besides T-bet, such
as NF-kB, may also be involved and may contribute to the
inhibition of IFN-c cytokine production by CpdA. If we consider
that IFN-c is a major activator of macrophages and that CpdA
inhibits IFN-c production by T cells, the inhibitory effect of CpdA
on macrophage-mediated inflammatory responses may be rein-
forced by the inhibition of IFN-c production and therefore may
further favor the resolution of inflammation.
Upon investigating the effect and functional consequences of
CpdA on the activity of the Th2 key TF GATA-3 we found that
CpdA induces GATA-3 activity on its own GATA-3 response
elements. GR specificity was guaranteed by showing that the
CpdA effect could be reversed by the synthetic antagonist
RU38486 that acts as a competitor for binding to GR.
GCs inhibit GATA-3 activity by inhibition of p38 MAPK-
mediated GATA-3 phosphorylation and hindering its nuclear
translocation [27,28]. Bearing this in mind, we studied the effect of
CpdA on p38 MAPK signaling and its subsequent effect on
GATA-3 activity. Using the p38 MAPK inhibitor SB203580, we
showed that CpdA induces GATA-3 transcriptional activity by
induction of p38 MAPK phosphorylation. Intracellular increments
of cAMP levels are associated with an augmentation of Th2
cytokine production via GATA-3 and PKA activation [20].
Therefore we performed transfection and Western Blot experi-
ments using the heat stable inhibitor of the PKA (PKI) or the PKA
inhibitor H89 and demonstrated that CpdA induces GATA-3
activity independently of PKA (data not shown). CpdA induction
of p38 MAPK phosphorylation is mediated by the GR because
pre-incubation with RU38486 reversed this effect (data not
shown). In addition, Western Blot experiments using a specific
antibody against phosphorylated GATA-3 show that CpdA
strongly induces GATA-3 phosphorylation.
GCs induce the expression of mitogen-activated protein kinase
(MAPK) phosphatase-1 (MKP-1), the endogenous inhibitor of p38
MAPK, which is necessary for GATA-3 nuclear translocation
[27,28]. To study whether the induction of p38 MAPK by CpdA
could be due to the inhibition of MKP-1 expression, we checked
the levels of endogenous MKP-1. These experiments however
showed that MKP-1 protein levels are not affected by CpdA (data
not shown). This is in accordance with previous results showing
that MKP-1 expression on primary microglia and astrocytes is not
affected by the addition of CpdA [9]. We also tested the possibility
that the mitogen- and stress-activated protein kinase- 1 (MSK1),
which has been shown to be activated by p38 MAPK and
inhibited by GC [37], was implicated in CpdA induction of
GATA-3 phosphorylation. However, no MSK1 induction was
found in CpdA-stimulated EL4 cells (data not shown).
Because GATA-3 directly controls the expression of IL-5 gene,
by binding to elements on the –70 to –59 region [38] on its
minimal promoter, we used as a readout of CpdA effect on
GATA-3 activity the IL-5 promoter. We describe for the first time
that selective modulation of GR, by means of the transrepression-
favouring GR modulator CpdA, strongly induces IL-5 gene and
cytokine production via an enhancement of the activation of
GATA-3. We show that CpdA induces GATA-3 activity, driving
the IL-5 promoter. The addition of SB203580 inhibits this
induction, again suggesting an involvement of the p38 MAPK
pathway. GATA-3 binding site mutations in the IL-5 promoter
further confirm that GATA-3 is a likely target of CpdA, and is
needed in order to enhance the activity of this promoter. The
mechanism described here does not rule out that in a full
physiological promoter context additional indirect effects may
occur. For example, a combination of CpdA-mediated induction
of other kinase pathways implicated in GATA-3 phosphorylation
or in p38 MAPK induction such as the upstream MAPK kinases
MKK3 and MKK6 [39], an interaction with other TFs involved
in the transcriptional complex of GATA-3, a recruitment and
activation of other TFs to the IL-5 promoter [40] or even a
recruitment of co-activators by GR may all contribute to the
overall induction of IL-5 gene.
In lymph nodes of rats with EAN, CpdA inhibits mRNA
expression of the IFN-c gene and at the same time induces Th2-
type cytokines expression [8]. In line with this observation, our
data showing that CpdA inhibits T-bet activity which impacts on
IFN-c gene, and at the same time induces GATA-3 mediated
Th2-type cytokine production, may contribute to provide a
molecular understanding for the previously described immuno-
suppressive action of CpdA in EAN.
Summing up, CpdA directly inhibits T-bet activity and IFN-c
production. On the other hand, considering the mutual inhibitory
action between T-bet and GATA-3 [14,17,25,41], the inhibition
Figure 5. Compound A induces GATA-3 phosphorylation and
nuclear translocation. A, EL4 cells were transfected with 15 mg of the
GR and 15 mg of GATA-3 expression vectors. After 16 h in culture, EL4
cells were pretreated during 30 minutes with or without Compound A
(CpdA, 10 mM) and then treated under basal or activated conditions
using cAMP (0.3 mM) during 25 minutes. Cell lysates were prepared for
Western Blot analysis against phospho-GATA-3 (p-GATA-3) (bands of
55 kDa). Total GATA-3 signal was used as loading control. One out of
three independent experiments with similar results are shown. B, EL4
cells were transfected with 15 mg of the GR and 15 mg of GATA-3
expression vectors. After 16 h in culture, EL4 cells were pretreated
during 30 minutes with or without CpdA (10 mM) and then treated
under basal or activated conditions using cAMP (0.3 mM) during 25
minutes. Cell nuclear and cytoplamic extracts were prepared for GATA-3
analysis by Western Blot. Histone H3 and GAPDH signals were used as
nuclear and cytoplasmic extracts control respectively. One out of three
independent experiments with similar results are shown.
doi:10.1371/journal.pone.0035155.g005
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of the Th1 profile by CpdA may be reinforced by inducing
GATA-3 and Th2-type cytokine production, which in turn may
further inhibit Th1 development. T-bet is known for its important
role in inflammation and autoimmune disorders such as
Inflammatory Bowel Disease, Multiple Sclerosis, Inflammatory
Arthritis and Diabetes [42]. Therefore, CpdA-mediated inhibition
of the Th1 phenotype may be helpful to understand the anti-
inflammatory role reported for CpdA in many of these diseases
and holds potential for the application of novel drugs which retain
CpdA-like characteristics in other inflammatory and Th1-
mediated autoimmune disorders. Indeed, although CpdA is not
druggable as such, its molecular regulation of GR activities
presents important insights on GR biology in immune regulation,
and confidence that the dissociative ligand hypothesis remains of
great value. However a clinical application of CpdA-like molecules
for the treatment of inflammatory and Th1-mediated autoimmune
diseases must be carefully studied taking into account the
association of GATA-3 and IL-5 with allergic diseases such as
asthma pathogenesis. Therefore, a balance considering the
reduction of T-bet-mediated autoimmune and inflammatory
responses together with the induction of Th2 responses should
be considered while setting up the clinical use of GR-ligands that
harbor similar characteristics as CpdA.
Materials and Methods
Splenocytes and Cell Line Cultures
Studies employing animals were conducted according to the
NIH guidelines and were approved by the Animal Research and
Care Committee (CICUAL # 2009/044) at the School of Exact
and Natural Sciences, University of Buenos Aires.
Spleens were removed aseptically from naive BALBc mice and
dispensed through a metal mesh in order to obtain single-cell
suspensions. Splenocytes were resuspended at a density of 2.56
106 cells and plated in 6-well plates. Purification of T cells was
achieved as described [26,27] using a nylon wool column.
Monocyte contamination was verified to be less than 1%. Purity
of the cell population was assayed by immunofluorescence using
specific monoclonal antibodies (Serotech Laboratories Limited,
Toronto, Canada) [26]: CD2, CD4, CD8, CD14, CD19, and
Figure 6. Compound A inhibits IL-5 promoter activity and cytokine production. A, EL4 cells were cotransfected with 9 mg of IL-5-Luc
reporter plasmid plus 9 mg of GR and GATA-3 expression vectors. After 16 h, cells were stimulated for 5 h with CpdA (10 mM) and cAMP. Also, EL4
cells were pretreated during 1 h with p38 inhibitor, SB203580 (10 mM). n = 6, * p,0.001 vs. GATA-3 without cAMP and CpdA, ** p,0.001 vs. GATA-3
with cAMP and without CpdA, *** p,0.001 vs. GATA-3 with cAMP and CpdA, # p,0.001 vs. GATA-3 with cAMP and SB203580 and without CpdA. B,
EL4 cells were cotransfected with 9 mg of the wild-type or GATA-3 mutated-binding site on the IL-5 promoter (IL-5-Luc-WT and IL-5-Gm-Luc) plus
9 mg of GR and GATA-3 expression vectors. After 16 h, cells were stimulated for 5 h with CpdA and cAMP. n = 6, * p,0.001 vs. GATA-3 without cAMP
and CpdA on IL-5-Luc WT, ** p,0.001 vs. GATA-3 with cAMP and without CpdA on IL-5-Luc WT, *** p,0.001 vs. GATA-3 with cAMP and CpdA on IL-5-
Luc WT, # p,0.05 vs. GATA-3 with cAMP and without CpdA on IL-5-Gm-Luc. C, A20 cells were cotransfected with 9 mg of IL-5-Luc reporter plus 9 mg
of GR and GATA-3 expression vectors. After 16 h, cells were stimulated for 5 h with CpdA and cAMP. n = 6, * p,0.001 vs. basal, ** p,0.001 vs. GATA-
3, *** p,0.001 vs GATA-3 with cAMP. D, Purification of T cells was achieved as described in Materials and Methods. Cells were activated with PMA (P),
Ionomycin (I) and cAMP during 24 h and then with CpdA for 5 h. Supernatants were used to measure mouse IL-5 by ELISA. n = 4, * p,0.05 vs. basal
without P+I, ** p,0.001 vs. P+I without cAMP, *** p,0.001 vs. P+I and cAMP, of one representative experiment of three independent experiments
with similar results. For the transfections experiments, results, as folds, normalized to b-galactosidase activity, are expressed as mean 6 SEM,
averaged from three independent experiments.
doi:10.1371/journal.pone.0035155.g006
CpdA Inhibits T-bet and Induces GATA-3 Activity
PLoS ONE | www.plosone.org 8 April 2012 | Volume 7 | Issue 4 | e35155
CD45, which define antigens on T cells/NK cells, Th lympho-
cytes, T cytotoxic/suppressor cells, monocytes/macrophages, B
cells and leukocytes (leukocyte common antigen), respectively.
Where indicated, these purified murine T cells were further
purified by FACS (FACSAriaII, Becton Dickinson, San Jose CA)
using anti-CD4 antibody (BD Pharmingen, San Jose, CA) to 95–
99% of purity. To determine cytokine secretion cells were seeded
and stimulated at the beginning of the culture with 10 ng/ml
PMA, 500 ng/ml ionomycin (I) for 24 h and then incubated with
10 mM CpdA for 6, 12 or 24 h. Cytokines were measured
according to the manufacturer’s instructions by ELISA (Pierce
Biotechnology Inc. Rockford, IL).
The murine cell line EL4, extensively used for studies with these
Th TFs [20,26,27,43] was obtained from Dr. N.W. Zwirner
(Department of Microbiology, Parasitology and Immunology,
School of Medicine, University of Buenos Aires, Buenos Aires,
Argentina) and were treated, where indicated, with 10–100 nM
Dex (a synthetic GC) or 0.1–10 mM CpdA and 10 ng/ml PMA,
500 ng/ml I, and/or 0.3 mM cAMP (all, except CpdA, from
Sigma Chemical Co., St. Louis, MO). Transfection experiments
were also repeated in human Jurkat T cells and the A20 mouse B
lymphoma cell line, both obtained from Dr. Mirta Giordano
(Department of Immunology, Institute for Hematologic Research,
National Academy of Medicine, Buenos Aires, Argentina).
CpdA was synthesized as described by Louw et al. [44]. CpdA
was lyophilized and stored at 270uC.
Some experiments were performed in the presence of the
specific GR antagonist RU38486 (Sigma Chemical Co., St. Louis,
MO) (1 mM), added 30 minutes before the addition of GCs, to
prove ligand-specific interactions with the ligand-binding domain
of GR.
For analysis of MAPK activation, cells were incubated with or
without the PKA inhibitor H89, the p38 inhibitor SB203580, the
MEK-1 inhibitor PD98059 and c-Jun NH2-terminal kinase (JNK)
inhibitor SP600125 (10, 20 and 40 mM) (Calbiochem, San Diego,
CA) for 1 h before stimulating with cAMP.
Plasmids and transfection assays
The plasmid constructs were kindly provided and previously
described as follows: the murine IL-5 promoter (which contains
the –1200 to +33 sequence from the IL-5 gene) coupled to the
luciferase reporter vector, was provided by Dr. T. Yokota [45] (IL-
5-Luc); the murine wild-type IL-5 promoter (2120 to +44) and
mutated on the GATA-3 binding site, were provided by Dr. E.
Serfling [46] (IL-5-Luc-WT and IL-5-Luc-Gm); the murine
GATA-3 expression vector, obtained from Dr. J. Leiden [11]
(pcDNA3-GATA-3); the reporter gene vector carrying GATA-3
response elements, coupled to the luciferase reporter vector, was
provided by Dr. A. Ray [18] (GATA-RE-Luc); the human GR
expression vector subcloned in a cytomegalovirus promoter
(CMV)-hGR and the CMV-b-galactosidase were supplied by
Dr. D. Spengler [47]; the p38 MAPK expression vector (pcEFL-
p38), the chimera pG5-Luc/ATF-2 and the catalytic subunit of
PKAc was provided by Dr. O. Cosso and Dr. T. Tanos [48,49];
the heat stable inhibitor of the PKA (PKI) was provided by Dr. R.
Mauer [50]; the murine IFN-c promoter was provided by Dr. H.
S. Fox [51] and was subcloned into the pGL3-Basic luciferase
reporter vector (Promega, Madison, WI) [26] (IFN-c-Luc); murine
pJG4.5mT-bet, obtained from Dr. L. H. Glimcher [21], was
subcloned into the pcDNA3 expression vector (Invitrogen,
Carlsbad, CA) [26] (pcDNA3-T-bet); the T-bet binding sites
[21] subcloned into the pTATA-GL3-Basic luciferase reporter
vector (Promega, Madison, WI) was obtained as previously
described [26] ((T-bet-RE)3-Luc); the TK-GRE2-Luc promoter,
was supplied by Dr. D. Spengler [47]; the wild-type human GR
(phGR-SB) and its GR DNA-binding domain (DBD)-derived
mutants A458T and S425G, were provided by Dr. A. C.B. Cato
[30], the construct containing the multimerized NF-kB-binding
sites linked to a minimal promoter upstream of the luciferase gene
(kB-Luc promoter) was previously described [52].
Transfection of EL4, Jurkat and A20 cells (56107 cells/ml) was
performed by electroporation, as previously described [26,27].
Cells were washed with PBS and extracts were prepared with
reporter lysis buffer (Promega, Madison, WI). After treatments,
cells were harvested and luciferase activity was measured as
previously described [26,27], using the Luciferase measure kit
(Promega, Madison, WI) with a Junior luminometer (Berlthod,
Bad Wildbad, Germany). CMVhGR expression vector was
cotransfected in EL4 cells in order to make them responsive to
GCs. In all cases, cells were cotransfected with the RSV-b-
galactosidase plasmid expression vector, used as control for
transfection efficiency to standardize the results. Lysates from
the transfections were also analyzed by Western Blot as described
below.
Western Blot Assays
Following the appropriate inductions, cells were washed once
with PBS (pH 7.0), and lysates were prepared as previously
described [26,27]. The membranes were incubated with the
mouse monoclonal anti-GATA-3 antibody (200 ng/ml) (Santa
Cruz Biotechnology, Santa Cruz, CA), anti-phospho-GATA-3
antibody (Abcam Inc, Cambridge, UK) (dilution: 1:500), followed
by incubation with HRP-conjugated specific secondary antibodies
(dilution: 1:3000) (Bio-Rad Laboratories, Hercules, CA), and
detection was performed with the ECL kit according to the
manufacturer’s instruction (Pierce Biotechnology, Rockford, IL).
The anti-GAPDH antibody (dilution: 1:10000) (Abcam Inc,
Cambridge, UK) was routinely used as a loading control. Anti-
histone H3 antibody (dilution: 1:20000) (Millipore, Billerica, MA)
was used as a control for the efficiency of the nuclear fractionation
and the anti-GAPDH antibody (dilution: 1:10000) (Abcam Inc,
Cambridge, UK) as a cytoplasmic fractionation control. To
separate nuclei from cytoplasm, we proceeded as previously
described [27]. To separate nuclei from cytoplasm, 16 107 cells
were washed in ice-cold phosphate-buffered saline and incubated
for 10 min on ice in 200 ml of buffer A containing 10 mM
HEPES, pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 1 mM dithio-
threitol, 2 mM orthovanadate, 0.5 mM phenylmethylsulfonyl
fluoride and protease inhibitor cocktail (Roche Diagnostics,
Mannheim, Germany). At the end of the incubation, a 0.1 volume
of 1% Nonidet P-40 was added and lysates were centrifuged at
3000 xg for 5 min. Supernatants were collected and used as
cytoplasmic extract. Pelleted nuclei were resuspended in 50 ml of
lysis buffer containing 20 mM HEPES, pH 7.9, 25% v/v glycerol,
420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 1 mM dithio-
threitol, 2 mM orthovanadate, 0.5 mM phenylmethylsulfonyl
fluoride and protease inhibitor cocktail (Roche Diagnostics,
Mannheim, Germany). After incubation for 30 min at 4uC with
vigorous shaking, nuclei were centrifuged at 12000 xg for 10 min
and the supernatants were collected and used as nuclear extract.
To analyze MAPK activation, blots were incubated with rabbit
anti-phospho-p38 (p-p38) (Thr180/Tyr182) and rabbit anti-pan-
p38 antibodies (dilution: 1:1000) (Cell Signaling, Beverly, MA).
Statistics
Statistics were performed by ANOVA in combination with the
Scheffe´s test. Data are shown as mean 6 SEM.
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